StockData
BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp. (BCTX) stock

BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ
Financials through Q4 FY2026, quarter ended Jul 31, 2026Last filing: 10-K on Oct 28, 2026Score 4/30
$3.28−0.23 (-6.55%)

Close on Nov 18, 2026Market cap $28.64MP/E –Yield –

BriaCell Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

BriaCell Therapeutics's free cash flow for the twelve months ending Jul 31, 2026 was -$28.78M. For fiscal 2026 it was -$28.78M.

Annual free cash flow

PeriodPeriod endValueChange
FY2026Jul 31, 2026-$28.78M–
FY2024Jul 31, 2024-$24.58M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jul 31, 2026-$5.96M–

More BriaCell Therapeutics figures

See a number that looks wrong?